The UK-based firm has pushed to secure regulatory authorisation to market its antibiotics in the US after breaking into the market back in 2012. And the Centre for Veterinary Medicine division of the US Food and Drug Administration (FDA) has approved the use of the drug to treat respiratory diseases in pigs.
Peter Lawrence, chairman of ECO, said the business was “extremely pleased” to secure the second marketing authorisation for Aivlosin in the US.
“The swine respiratory disease segment is a key one and this latest approval demonstrates ECO’s continued progress to becoming a major force in the international market for veterinary pharmaceutical products.”
The product will be sold via Pharmgate Animal Health, a sales and marketing joint venture ECO formed in 2010 with Pharmgate, a US subsidiary of Chinese veterinary drug producer Jinhe Biotechnology Co.
Last month, ECO posted $17.5m in first-quarter pre-tax profit, as global pressure to curb antibiotic resistance and stamp up growth promoters boosted demand for the company’s Aivlosin antibiotic – a prescription-only drug used to treat respiratory and enteric diseases in both pigs and poultry.